Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
PDSB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.29
Previous CloseN/A
Volume197.50K
Average Volume (3M)403.62K
Market Cap
$53.63M
Enterprise Value$47.71M
Total Cash (Recent Filing)$39.98M
Total Debt (Recent Filing)$18.96M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Nov 12, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding46,633,360
10 Day Avg. Volume370,726
30 Day Avg. Volume403,615
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue807.80
Enterprise Value/Gross Profit-3.01K
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$13.00Price Target Upside992.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementThe colorectal cancer cohort of the Phase 2 PDS01ADC study met criteria for expansion into Stage 2 following encouraging Stage 1 results.
HPV Treatment EfficacyThe Versamune HPV + pembrolizumab combination exceeds current benchmarks for median overall survival and objective response rates in HPV16+ R/M HNSCC.
Market PotentialPDS01ADC could represent a significant advancement in solid tumor intervention, while also being a notable commercial and value generating opportunity for PDS and investors.
Bears Say
Competitive LandscapeHPV16+ remains the most prominent and rapidly growing issue in HNSCC, with its incidence expected to continue rising over the next 20-30 years, indicating a significant and expanding public health issue.
Funding ChallengesThe company expressed a need to explore additional funding opportunities to complete select ongoing operations, including the VERSATILE-003 trial.
PDS Biotechnology News
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $0.85 and its highest was $4.29 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $53.63M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Nov 12, 2025 which is in 80 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Aug 13, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.233 by $0.023.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.2.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 46,633,360 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.233. Following the earnings report the stock price went down -5.691%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
PDS Biotechnology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (992.44% Upside)
$13.00 (992.44% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.93%
12-Months-Change
Fundamentals
Return on Equity
-156.16%
Trailing 12-Months
Asset Growth
-33.09%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
PDSB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and promising data in the oncology segment, particularly with the advancement of VERSATILE-003 and positive results from VERSATILE-002. However, financial challenges were noted, including an increased net loss and a decreased cash balance. While the clinical outlook is promising, financial concerns remain a consideration.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$13.00
▲(992.44% Upside)
Technical Analysis
CytomX Therapeutics
―
Cue Biopharma
―
Sutro Biopharma
―
PMV Pharmaceuticals
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
1.81% Insiders
4.22% Mutual Funds
5.33% Other Institutional Investors
84.37% Public Companies and
Individual Investors